Preclinical data from an experimental treatment for chronic heart failure have shown that the compound is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure. The study results were obtained in a clinically relevant large animal model and published on 22 October in the European Heart Journal.
